Inhibrx Biosciences

Inhibrx is a clinical-stage biotechnology company dedicated to developing a wide range of biotherapeutic candidates. Inhibrx utilizes various protein engineering approaches to therapeutically meet the specific requirements of complex targets and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline focuses on oncology, infectious diseases, and orphan diseases. Inhibrx collaborates with Celgene and the Alpha-1 Foundation and has received awards from multiple authorized institutions, including NIH, NIAID, and CARB-X.